002210 — Dongsung Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00
- KR₩118bn
- KR₩155bn
- KR₩89bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -8,385 | -14,079 | -4,313 | -2,122 | -2,074 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 4,683 | 11,099 | 2,363 | 1,316 | 2,530 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -6,712 | 5,891 | -3,025 | -5,196 | -6,851 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -8,306 | 5,010 | -2,752 | -3,883 | -4,293 |
Capital Expenditures | -1,422 | -6,922 | -2,324 | -643 | -924 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 10,768 | 1,283 | -7,376 | 1,281 | -4.15 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 9,346 | -5,639 | -9,700 | 638 | -928 |
Financing Cash Flow Items | -26.3 | -1.35 | 72.2 | -1,052 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 1,012 | -3,303 | 1,232 | 4,240 | 7,567 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2,067 | -4,015 | -11,212 | 954 | 2,342 |